UNSPSC 51292924: Mianserin hydrochloride

This classification denotes a serotonin antagonist and antidepressant agent and adrenergic antagonist with the molecular formula C18H20N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2X03TN217S, chemically known as 1,2,3,4,10,14b-hexahydro-2-methyldibenzo(c,f)-pyrazino(1,2-a)azepine monohydrochloride but more generally known as mianserin hydrochloride, which bears US NIH Compound Identifier 68551.

UNSPSC 51292924 Mianserin hydrochloride is a Commodity code that in recent state and local procurement activity covers pharmaceutical supply agreements far broader than the code's nominal scope. Rather than mianserin hydrochloride alone, the recent solicitations tagged to this code procure multi-source generic pharmaceuticals, over-the-counter products, and opioid-reversal agents through competitive bidding and cooperative purchasing vehicles. State and local governments issuing under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The work involves manufacturer pricing agreements, wholesaler-managed distribution networks, compliance with cGMP and Drug Supply Chain Security Act requirements, and quarterly or direct-to-consumer delivery logistics. Vendors must maintain specific insurance coverage, achieve FDA compliance, and meet shelf-life and manufacturing location documentation standards.

The geographic spread includes Florida, Texas, Minnesota, and Oregon, with the most recent activity concentrated in multistate cooperative arrangements. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission's Request for Information HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to state and local facilities across Minnesota and Oregon. The MMCAP RFP emphasizes price competitiveness (75 percent of evaluation weight), EDI capability, and compliance with a 3 percent administrative fee structure, with contract terms of two years for new vendors and optional extensions for incumbents through June 30, 2028.